The efficacy of endogenous interferon-gamma inducer in the complex therapy of patients with recurrent bacterial vaginosis

Rzaeva L.F.

Azerbaĭdzhanskiĭ gosudarstvennyĭ institut usovershenstvovaniia vracheĭ im. A. Alieva, Baku

Authors:

Rzaeva L.F.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2016;15(4): 111‑114

DOI: 10.17116/klinderma2016154111-114

Downloaded: 9

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Rzaeva LF. The efficacy of endogenous interferon-gamma inducer in the complex therapy of patients with recurrent bacterial vaginosis. Russian Journal of Clinical Dermatology and Venereology. 2016;15(4):111‑114. (In Russ.)
https://doi.org/10.17116/klinderma2016154111-114

Close metadata

Recommended articles:

Factors associated with normal leukocyte count and C-reactive protein in adults with acute appendicitis: a retrospective cohort study. Pirogov Russian Journal of Surgery. 2024;(8):15-20

Diagnosis of early neonatal infections in premature newborns. Russian Journal of Anesthesiology and Reanimatology. 2024;(4):6-13

The role of some inflammatory markers in diagnosis of acute peritonitis in patients with HIV infection. Pirogov Russian Journal of Surgery. 2024;(12):29-37

Bacterial vaginosis is a general infectious non-inflammatory syndrome associated with quantitative and qualitative changes in the structure of the vaginal biocenosis. Bacterial vaginosis is characterized by decreased level or absence of lactoflora and its replacement with polymicrobial associations of anaerobes. Our study was aimed at investigating the status of local non-specific protection in patients with recurrent bacterial vaginosis and its correction with tilorone, an endogenous interferon-gamma inducer. The study revealed pronounced leukocyte reaction and increased level of IFN-γ in the vaginal fluid of patients with recurrent bacterial vaginosis. The results of the study demonstrated that combination of basic treatment with administration of tilorone is accompanied by reduced leukocyte reaction, significant normalization of IFN-γ level, as well as improvement according to Amsel criteria compared to the control group. Thus, the laboratory and clinical results suggest that tilorone can be recommended as a component of therapy of relapsing forms of bacterial vaginosis.

Keywords:

bacterial vaginosis

tilorone

leukocytes

IFN-γ

Authors:

Rzaeva L.F.

Azerbaĭdzhanskiĭ gosudarstvennyĭ institut usovershenstvovaniia vracheĭ im. A. Alieva, Baku

List of references:

Ankirskaya AS, Prilepskaya VN, Bayramova GR. Normal and pathological vaginal mycoecosystem. Ginekologiya, 2009; 3: 9-11. (In Russ)
Sobel JD, Hay P. Diagnostic techniques for bacterial vaginosis and vulvovaginal candidosis - requirement for a simple differential test. Expert Opin.Med. Diagn.2010 Jul;4(4):333-341.
Kira EF. Bakterial'nyy vaginoz St. Petersburg: Neva – Lyuks. 2001:364. (In Russ)
Kira EF, Muslimova SZ. The modern view of non-transmissive vaginal infections in females of reproductive age. Akusherstvo i ginekologiya, 2008; 1:3-6. (In Russ)
Khamaganova IV. Bacterial vaginosis. Lechashchii vrach, 2007;10:42-45. (In Russ)
Uvarova EV, Ankirskaya AS, Grigorenko YuP. The effectiveness of treatment of bacterial vaginosis in non-pregnant females (the results of a multicenter study). Akusherstvo i ginekologiya, 2010;1:52-57. (In Russ)
Kira EF, Gamirova EV, Gaytukieva RA, Belyakina IV. The results of the randomized study of the efficacy and safety of chlorhexidine and metronidazole in treatment of bacterial vaginosis. Akusherstvo i ginekologiya, 2010;6:123-129. (In Russ)
Mohanty SK, Leela KS. Textbook of Immunology Second Edition. 2014., 265 p.
UK National Guideline for the management of Bacterial Vaginosis. British Association for Sexual Health and HIV. 2012, 15 p.
Bacterial Vaginosis. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines.2015., June 4, 5 p.
Federal'nye klinicheskie rekomendatsii po vedeniyu bol'nykh bakterial'nym vaginozom. Rossiiskoe obshchestvo dermatovenerologov i kosmetologov. Moscow. 2013:16. (In Russ)
Brocklehurst P, Gordon A, Heatley E, Milan SJ. Antibiotics for treating bacterial vaginosis in pregnancy (Review). The Cochrane Collaboration. 2013;1:123 r.
Khanferyan RA, Borovikov OV, Borovikov IO, Zakieva VA, Shcherban' MR. Clinical and immunological efficacy of the treatment of relapsing vulvovaginal candidiasis using systemic Genferon. Effektivnaya farmakoterapiya v akusherstve i ginekologii, 2008;3:38-48. (In Russ)
Udzhukhu VYu, Petrunin DD. Genferon suppositories as a highly effective component in the complex therapy of urogenital infections.. Novosti dermatovenerologii i reproduktivnogo zdorov'ya, 2010;1-2:18-20. (In Russ)
Aboul Enien WM, El Metwally HA. Association of abnormal vaginal flora with increased cervical tumour necrosis factor--alpha and interferon--gamma levels in idiopathic infertility. Egypt J. lmmunol., 2005;12(2):53-59.
Cherpes TL, Marrazzo JM, Cosentino LA, Meyn LA, Murray PJ, Hillier SL. Hormonal contraceptive use modulates the local inflammatory response to bacterial vaginosis. Sex Transm Infect. 2008;84(1):57-61.
Fan SR, Liu XP, Liao QP. Human defensins and cytokines in vaginal lavage fluid of women with bacterial vaginosis. International journal of gynaecology and obstetrics, 2008; 103(1):50–54.
Alvarez-Olmos MI, Barousse MM, Rajan L, Van Der Pol BJ, Fortenberry D, Orr D, Fidel PL. Jr. Vaginal lactobacilli in adolescents: presence and relationship to local and systemic immunity, and to bacterial vaginosis. Sex Transm Dis 2004; 31(7):393-400.
Campos AC, Murta EF, Michelin MA, Reis C. Evaluation of Cytokines in Endocervical Secretion and Vaginal pH from Women with Bacterial Vaginosis or Human Papillomavirus. ISRN Obstet Gynecol. 2012; 2012:1-7.
Vasilenko LV, Stepanov SA, Rogozhina IE, Morrison AV, Frolova LYu. Bakterial'nyy vaginoz. Saratov, publishing office of the Saratov Stave Medical University. 2007: 93. (In Russ)

Close metadata